首页> 美国卫生研究院文献>Nanomaterials >Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities
【2h】

Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities

机译:介孔二氧化硅中抗结核药物的封装和细胞内抗菌活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tuberculosis is a major problem in public health. While new effective treatments to combat the disease are currently under development, they tend suffer from poor solubility often resulting in low and/or inconsistent oral bioavailability. Mesoporous materials are here investigated in an in vitro intracellular assay, for the effective delivery of compound PA-824; a poorly soluble bactericidal agent being developed against Tuberculosis (TB). Mesoporous materials enhance the solubility of PA-824; however, this is not translated into a higher antibacterial activity in TB-infected macrophages after 5 days of incubation, where similar values are obtained. The lack of improved activity may be due to insufficient release of the drug from the mesopores in the context of the cellular environment. However, these results show promising data for the use of mesoporous particles in the context of oral delivery with expected improvements in bioavailability.
机译:结核病是公共卫生中的主要问题。尽管目前正在开发对抗该疾病的新的有效治疗方法,但是它们往往具有溶解性差的缺点,常常导致低和/或不一致的口服生物利用度。本文在体外细胞内测定中研究了介孔材料,以有效递送化合物PA-824;一种针对结核病(TB)的难溶性杀菌剂。介孔材料可增强PA-824的溶解度;但是,在培养5天后,在感染TB的巨噬细胞中,这并没有转化为更高的抗菌活性,在这里获得了相似的值。缺乏改善的活性可能是由于在细胞环境下药物从中孔释放不足。然而,这些结果显示了在口服递送的情况下使用中孔颗粒的有希望的数据以及预期的生物利用度的改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号